

Myung Ah Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2971430/publications.pdf>

Version: 2024-02-01

63
papers

1,406
citations

394421

19
h-index

361022

35
g-index

67
all docs

67
docs citations

67
times ranked

2625
citing authors

#	ARTICLE	IF	CITATIONS
1	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	7.1	417
2	Preoperative sarcopenia and postoperative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 326-334.	7.3	103
3	Three Dimensional Mixed-Cell Spheroids Mimic Stroma-Mediated Chemoresistance and Invasive Migration in hepatocellular carcinoma. <i>Neoplasia</i> , 2018, 20, 800-812.	5.3	79
4	Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 125.	2.6	63
5	Survivin expression and its clinical significance in pancreatic cancer. <i>BMC Cancer</i> , 2005, 5, 127.	2.6	51
6	The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1100.	2.6	40
7	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 674-681.	3.9	39
8	Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 346-350.	2.5	38
9	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020, 130, 51-62.	2.8	34
10	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. <i>Oncologist</i> , 2020, 25, e502-e511.	3.7	32
11	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	3.9	32
12	Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study. <i>BMC Cancer</i> , 2021, 21, 77.	2.6	31
13	Impact of preoperative body compositions on survival following resection of biliary tract cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 794-802.	7.3	29
14	Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 235.	3.3	28
15	Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02. <i>Radiotherapy and Oncology</i> , 2014, 113, 18-23.	0.6	26
16	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
17	Early-Onset Myasthenia Gravis Following COVID-19 Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, e50.	2.5	25
18	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). <i>Radiotherapy and Oncology</i> , 2014, 110, 150-154.	0.6	21

#	ARTICLE	IF	CITATIONS
19	Clinical characteristics of young-age onset gastric cancer in Korea. BMC Gastroenterology, 2016, 16, 110.	2.0	20
20	Gemcitabine and Cisplatin Combination Chemotherapy in Intrahepatic Cholangiocarcinoma as Second-line Treatment: Report of Four Cases. Japanese Journal of Clinical Oncology, 2004, 34, 547-550.	1.3	19
21	Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 239-246.	1.1	18
22	Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer. Cancer Research and Treatment, 2015, 47, 259-265.	3.0	16
23	Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience. Korean Journal of Internal Medicine, 2017, 32, 452-458.	1.7	15
24	Histogram Analysis of Perfusion Parameters from Dynamic Contrast-Enhanced MR Imaging with Tumor Characteristics and Therapeutic Response in Locally Advanced Rectal Cancer. BioMed Research International, 2018, 2018, 1-9.	1.9	14
25	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 851-860.	3.0	14
26	Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III?. European Journal of Cancer, 2018, 104, 62-69.	2.8	13
27	A Case of Mixed Adenoneuroendocrine Carcinoma of the Common Bile Duct: Initially Diagnosed as Cholangiocarcinoma. Korean Journal of Pathology, 2014, 48, 445-448.	1.3	12
28	Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 1021-1030.	2.0	11
29	Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study. BMC Palliative Care, 2015, 14, 53.	1.8	10
30	Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy. BMC Cancer, 2016, 16, 207.	2.6	10
31	Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).. Journal of Clinical Oncology, 2022, 40, 4019-4019.	1.6	10
32	β2-Catenin expression is associated with cell invasiveness in pancreatic cancer. Korean Journal of Internal Medicine, 2019, 34, 618-625.	1.7	9
33	Does the Gadoteric Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with ¹⁸ F-FDG PET/CT. BioMed Research International, 2016, 2016, 1-6.	1.9	8
34	Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1625-1630.	2.5	7
35	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. Journal of Cancer, 2019, 10, 6185-6190.	2.5	7
36	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Cancer, 2021, 21, 1176.	2.6	7

#	ARTICLE	IF	CITATIONS
37	Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 66, 50.	0.4	6
38	Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study. Cancer Research and Treatment, 2016, 48, 1420-1428.	3.0	6
39	Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer. Biomedicines, 2022, 10, 1289.	3.2	6
40	Pilot study for the Psychometric Validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients. Cancer Research and Treatment, 2021, 53, 25-31.	3.0	5
41	Prognostic implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers. Korean Journal of Internal Medicine, 2020, 35, 408-420.	1.7	5
42	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. Cancer Research and Treatment, 2019, 51, 1249-1256.	3.0	5
43	Choosing Wisely: The Korean Perspective and Launch of the "Right Decision in Cancer Care"™ Initiative. Cancer Research and Treatment, 2020, 52, 655-660.	3.0	5
44	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers, 2021, 13, 331.	3.7	4
45	Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. Current Oncology, 2021, 28, 1652-1662.	2.2	4
46	The development and validation of a predictive model for recurrence in rectal cancer based on radiological and clinicopathological data. European Radiology, 2021, 31, 8586-8596.	4.5	4
47	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).. Journal of Clinical Oncology, 2021, 39, TPS4161-TPS4161.	1.6	4
48	Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. Cancer Research and Treatment, 2018, 50, 283-292.	3.0	4
49	Withdrawal of life-prolonging medical care and hospice-palliative care. Journal of the Korean Medical Association, 2019, 62, 369.	0.3	4
50	Clinical significance of isolated biliary candidiasis in patients with unresectable cholangiocarcinoma. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 533-539.	1.3	2
51	Capecitabine and cisplatin as a second-line chemotherapy for patients with advanced biliary tract cancer.. Journal of Clinical Oncology, 2020, 38, 543-543.	1.6	2
52	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. Journal of Clinical Oncology, 2022, 40, TPS490-TPS490.	1.6	2
53	Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma. Chonnam Medical Journal, 2022, 58, 29.	0.9	2
54	Current status of cancer immunotherapy with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 326-331.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Predicting cumulative incidence of chemotherapy toxicity in older patients with cancer: Korean Cancer Study Group prospective cohort study (KCSG) PC 13-09.. Journal of Clinical Oncology, 2017, 35, e21539-e21539.	1.6	1
56	Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).. Journal of Clinical Oncology, 2022, 40, 4096-4096.	1.6	1
57	Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. PLoS ONE, 2020, 15, e0240318.	2.5	0
58	Application of manual aspiration thrombectomy in the treatment of deep vein thrombosis in cancer patients: Descriptive retrospective cohort study. PLoS ONE, 2021, 16, e0255539.	2.5	0
59	A structural equation modeling approach to understanding physical function of terminal cancer patients. Supportive Care in Cancer, 2022, 30, 1149-1158.	2.2	0
60	Comparison of the efficacy between the gemcitabine/cisplatin (GP) and capecitabine/cisplatin (XP) for the advanced biliary tract cancer: Retrospective analysis in a single institution.. Journal of Clinical Oncology, 2012, 30, 365-365.	1.6	0
61	Use of high white blood cell (WBC) count to predict poor survival outcome in gastrointestinal (GI) cancer with thrombotic event.. Journal of Clinical Oncology, 2012, 30, e19614-e19614.	1.6	0
62	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. Journal of Clinical Oncology, 2022, 40, TPS621-TPS621.	1.6	0
63	Case 2: A 66-Year-Old Man With Chronic Watery Diarrhea. Journal of Korean Medical Science, 2022, 37, .	2.5	0